Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in Active Idiopathic Inflammatory Myopathies
NCT05379634Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of nipocalimab in idiopathic inflammatory myopathies (IIM), sponsored by Janssen Pharmaceutical. Started Jul 2022; status: completed.
02
Drugs
nipocalimab
03
Conditions
idiopathic inflammatory myopathies (IIM)
Beyond the preview
Go deeper on NCT05379634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379634.